Chemotactic Peptide N-formyl-Met-Leu-Phe Activation of p38 Mitogen-activated Protein Kinase (MAPK) and MAPK-activated Protein Kinase-2 in Human Neutrophils*

(Received for publication, August 8, 1996, and in revised form, October 16, 1996)

Eric Krump Dagger §, Jasbinder S. Sanghera , Steven L. Pelech , Wendy Furuya Dagger and Sergio Grinstein Dagger par **

From the Dagger  Division of Cell Biology, Research Institute, The Hospital for Sick Children and the par  Department of Biochemistry, University of Toronto, Toronto, Ontario M5G 1X8, Canada and the  Department of Medicine, University of British Columbia, and Kinetek Pharmaceuticals Inc., Vancouver, British Columbia V5Z 1A1, Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Activation of polymorphonuclear leukocytes (PMN) by chemotactic peptides initiates a series of functional responses that serve to eliminate pathogens. The intermediate steps that link engagement of the chemoattractant receptor to the microbicidal responses involve protein kinases that have yet to be identified. In this study we detected in human PMN the presence of p38 mitogen-activated protein kinase (MAPK), which became rapidly tyrosine phosphorylated and activated in response to the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP). Pretreatment of PMN with wortmannin, a phosphatidylinositol 3-kinase inhibitor, or bis-indolylmaleimide, a protein kinase C antagonist, resulted in partial inhibition of p38 phosphorylation upon fMLP stimulation. Similarly, phosphorylation of p38 was only partially inhibited when the fMLP-induced cytosolic calcium transient was prevented. Stimulation of PMN by the chemoattractant also resulted in the rapid phosphorylation and activation of MAPK-activated protein kinase-2 (MAPKAPK-2), which was completely inhibited by the specific p38 inhibitor, SB203580. The physical interaction of p38 with MAPKAPK-2 was studied by coimmunoprecipitation. These two kinases were found to be associated in unstimulated PMN but dissociated upon activation of the cells by fMLP. Together these findings demonstrate the activation of p38 by chemotactic peptides in human PMN by a process involving phosphatidylinositol 3-kinase, protein kinase C, and calcium. p38, in turn, is an upstream activator of MAPKAPK-2.


INTRODUCTION

Polymorphonuclear leukocytes (PMN)1 respond rapidly to invading microorganisms or tissue injury by activation of numerous effectors, including the generation of superoxide anions, secretion of lytic enzymes, and phagocytosis of particles. These responses serve to neutralize and destroy the invading pathogens (1). The recruitment of PMN to sites of bacterial infection and their subsequent activation are initiated by binding of chemoattractants to specific cell surface receptors, which are coupled to heterotrimeric G proteins (2). Receptor engagement triggers a complex cascade of biochemical events which culminates in the activation of the microbicidal responses. Many of these intervening steps have yet to be defined.

Increased phosphorylation of several proteins has been found to correlate with the stimulation of PMN effectors, thereby suggesting a causal role in the activation process (3, 4, 5, 6). Additional support for a central role of phosphorylation was provided by the finding that pharmacological agents that interfere with protein kinases and phosphatases are also potent modulators of PMN responsiveness (7, 8, 9, 10). Indeed, there is abundant evidence that protein kinase C isoforms are essential to the microbicidal response (11, 12), and activation of tyrosine phosphorylation seems to be equally important (7, 9). Studies in PMN stimulated with the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) led to the identification of Erk-1 and Erk-2 as major targets of tyrosine phosphorylation (13, 14, 15). These Ser/Thr kinases are members of a family of mitogen-activated protein kinases (MAPK) which are characterized by dual phosphorylation on tyrosine and threonine residues during activation. Other members of the MAPK family include p38 (16, 17) and JNK (18, 19, 20), which can be activated by physico-chemical stress, lipopolysaccharides, and by some cytokines (21). These kinases were identified more recently, and their presence and regulation in PMN have not been explored.

p38 was originally cloned from Saccharomyces cerevisiae (termed HOG1) (22), but homologs were subsequently found in Xenopus (mpk2) (23), murine (p38) (16), and human tissues (CSBP1 and CSBP2) (17, 24). In view of its conservation and wide distribution, it would appear that p38 serves an important function in cellular responses. Indeed, the development of an inhibitor of p38 has pointed to its involvement in the synthesis of interleukin-1 and tumor necrosis factor in monocytes (17), interleukin-8 in peripheral blood mononuclear cells (25), and in platelet aggregation and secretion (26). Phosphorylation of a downstream substrate is believed to mediate the aforementioned effects of p38, but the identity of these putative target(s) remains unclear. One possible effector may be MAPK-activating protein kinase-2 (MAPKAPK-2), a Ser/Thr kinase that possesses the ability to phosphorylate the small heat shock protein HSP27 (23, 27). HSP27 has, in turn, been suggested to modulate actin microfilament dynamics and cellular thermoresistance (28, 29).

In the current study we investigated whether p38 and/or MAPKAPK-2 is involved in the signaling process of human PMN activated by fMLP. Using immunoprecipitation, fractionation, and in vitro kinase assays we found that these enzymes are present as an inactive complex in unstimulated cells. Chemotactic stimulation promoted the activation and dissociation of p38 and MAPKAPK-2 by a pathway involving phosphatidylinositol 3-kinase (PI 3-kinase) and protein kinase C (PKC).


EXPERIMENTAL PROCEDURES

Materials

fMLP, phorbol 12-myristate 13-acetate (PMA), and thapsigargin were purchased from Sigma. The acetoxymethyl ester of BAPTA was from Molecular Probes. Ficoll-Paque, dextran T-500, protein A-Sepharose, and Mono Q were from Pharmacia Biotech Inc. (Québec, Canada). Bis-indolylmaleimide or GF 109203X (BIM) was from BioMol. [gamma -32P]ATP (4,500 Ci/mmol) was from ICN. Glutathione S-transferase-tagged ATF-2 was obtained for Santa Cruz Biotechnologies (Santa Cruz, CA), and recombinant human HSP27 was from StressGen (Victoria, BC, Canada). Monoclonal phosphotyrosine antibody (clone 4G10) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). Rabbit polyclonal p38 antibody was kindly provided by Dr. Brent Zanke (Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada). Rabbit polyclonal MAPKAPK-2 antibodies were raised against a peptide encoding the COOH-terminal domain (SRVLKEDKERWEDVKGC). The p38 inhibitor SB203580 was generously given by SmithKline Beecham (King of Prussia, PA).

PMN Isolation

Human PMN were isolated from blood freshly drawn by venipuncture from healthy donors essentially as described previously (30). Briefly, whole blood was sedimented on dextran T-500 to remove red cells, and the resulting supernatant was overlaid onto Ficoll-Paque cushions and centrifuged. Contaminating red cells in the pellet were removed by hypotonic lysis. The purified PMN were resuspended in HEPES-buffered (25 mM, pH 7.4) bicarbonate-free RPMI 1640 medium at 107 cells/ml and stored at room temperature on a rotator until use. For immunoprecipitation and cell fractionation experiments, the cell suspension was treated with 2.5 mM diisopropyl fluorophosphate for 15 min at room temperature, sedimented, and resuspended in fresh HEPES-buffered RPMI 1640 before use. For the experiments, PMN were resuspended in HEPES-buffered saline (140 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 3 mM KCl, 10 mM glucose, and 10 mM HEPES, pH 7.4). Unless indicated otherwise, all experiments were performed at 37 °C.

Ca2+ Depletion and Buffering

Where indicated, intracellular Ca2+ stores were depleted by treating a PMN suspension with 100 nM thapsigargin for 5 min at 37 °C in Ca2+-free HEPES-buffered saline. Alternatively, intracellular Ca2+ was buffered by treating suspended PMN with 10 µM BAPTA-acetoxymethyl ester for 30 min at 37 °C in regular (Ca2+-containing) HEPES buffer. Following this incubation period, the cells were resuspended in nominally Ca2+-free HEPES-buffered saline and incubated an additional 1 min before stimulation with fMLP.

Immunoprecipitation and Immunoblotting

Following stimulation of PMN, the incubation was stopped by adding of 2 volumes of ice-cold HEPES-buffered saline followed by a rapid sedimentation of the cells in a microcentrifuge. For immunoblotting of whole cell lysates, pellets containing 106 cells were immediately resuspended in boiling Laemmli sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol) and subjected to analysis by SDS-PAGE. Immunoprecipitation of tyrosine-phosphorylated proteins was performed as described previously (13). For immunoprecipitation of p38 and MAPKAPK-2, the cell pellet (107 cells) was solubilized in 1 ml of ice-cold Nonidet P-40 buffer (1 mM EDTA, 1% (v/v) Nonidet P-40, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin, 1 mM sodium vanadate, 5 mM NaF, and 50 mM Tris-HCl, pH 8.0). After 15 min at 4 °C, the lysates were centrifuged at 14,000 × g for 5 min to remove insoluble debris, and the appropriate antibody (1:500 dilution for anti-p38 and 1:250 for anti-MAPKAPK-2) was added to the soluble fraction, which was then incubated for 1 h at 4 °C. Subsequently, 30 µl of a 50% slurry of protein A-Sepharose (preblocked overnight with 5% albumin) was added, and the lysates were incubated an additional 2 h at 4 °C. The immune complexes were then washed five times with Nonidet P-40 buffer and subjected to a kinase assay or resuspended in Laemmli sample buffer and subjected to SDS-PAGE.

For immune complex kinase assays, immunoprecipitates were resuspended in 25 µl of kinase buffer (20 mM MgCl2, 1 mM sodium vanadate, 5 mM NaF, 20 mM beta -glycerophosphate, 20 mM p-nitrophenylphosphate, 2 mM dithiothreitol, 20 µM ATP, 5 µCi of [gamma -32P]ATP, and 50 mM HEPES, pH 7.4) and 3 µg of either glutathione S-transferase-tagged ATF-2 or HSP27. Following an incubation of 20 min at 30 °C, an equal volume of 2 × Laemmli sample buffer was added, and samples were boiled for 5 min (except for MAPKAPK-2 immunoprecipitation experiments, where samples were kept on ice until analyzed by SDS-PAGE). Immunoprecipitates were subjected to SDS-PAGE (10% acrylamide) and then electrotransferred onto polyvinylidene difluoride (PVDF) membranes. The blots were incubated with the appropriate antibody (1:2,000 dilution for p38 and MAPKAPK-2) followed by a horseradish peroxidase-coupled anti-rabbit or anti-mouse antibody (1:5,000 dilution), which was detected by enhanced chemiluminescence (ECL; Amersham). For kinase assays, phosphorylated substrates were detected with a PhosphorImager (Molecular Dynamics Inc.). Tyrosine phosphorylation was quantitated by densitometric scanning of the x-ray films using a Protein Database Inc. (Huntington Station, NY) model DNA 35 scanner with the Discovery series one-dimensional gel analysis software version 2.1.

Mono Q Chromatography

PMN (5 × 107) were treated with or without 100 nM fMLP for 1 or 2 min at 37 °C. The incubation was terminated by adding 2 volumes of ice-cold HEPES-buffered saline and rapidly sedimenting the cells in a microcentrifuge. The cell pellet was solubilized in Nonidet P-40 buffer and the debris removed by centrifugation at 14,000 × g for 5 min. The supernatant (approx 1 mg of protein) was fractionated on a Mono Q column (1-ml bed volume) equilibrated with buffer A (12.5 mM MOPS, pH 7.2, 12.5 mM beta -glycerophosphate, 0.5 mM EGTA, 7.5 mM MgCl2, and 1 mM dithiothreitol). The column was eluted with a 10-ml linear 0-0.8 M NaCl gradient in buffer A using the Pharmacia fast protein liquid chromatography system. Fractions (250 µl) were collected and assessed for HSP27 kinase activity and analyzed by SDS-PAGE and immunoblotting.


RESULTS

Detection of p38 in Human PMN and Activation by fMLP

Immunoblotting of lysates of human PMN with a p38-specific polyclonal antibody revealed a single band of approximately 42 kDa (not shown). To determine whether treatment with fMLP induces activation of p38, PMN were stimulated for increasing lengths of time, and the kinase was immunoprecipitated. As shown in Fig. 1A, fMLP induced a time-dependent, transient tyrosine phosphorylation of p38. Phosphotyrosine accumulation was apparent at the earliest time analyzed, 0.5 min, attained maximal level at 1 min, and returned to near basal levels between 5 and 10 min. Fig. 1B demonstrates that equal amounts of the MAPK were immunoprecipitated at all times. The phosphorylation of p38 was also demonstrated by immunoprecipitating tyrosine-phosphorylated proteins from PMN lysates. Blotting these immunoprecipitates with a p38-specific antibody also revealed a 42-kDa protein in stimulated, but not in resting (control) cells (Fig. 1C). We next determined whether the kinase activity of p38 was also stimulated by the chemotactic peptide. Only a marginal amount of ATF-2 phosphorylation was detected in p38 immunoprecipitates obtained from unstimulated PMN. By contrast, a sizable activity was consistently observed in precipitates from fMLP-stimulated cells (Fig. 1D). Together these results demonstrate the presence p38 in human PMN and the ability of fMLP to phosphorylate and activate this kinase.


Fig. 1. Tyrosine phosphorylation and activation of p38 in fMLP-stimulated PMN. Panel A, time course of p38 tyrosine phosphorylation induced by fMLP. PMN were stimulated with 100 nM fMLP for the indicated periods, then immediately lysed in 1% Nonidet P-40-containing buffer, and p38 was immunoprecipitated (IP). The immunoprecipitates were separated by SDS-PAGE, transferred to PVDF membranes, and blotted with a phosphotyrosine-specific monoclonal antibody. Panel B, the blot shown in panel A was stripped and reprobed using a p38-specific antibody to show the amounts of p38 precipitated. Panel C, immunoprecipitation of tyrosine-phosphorylated p38. PMN were stimulated with 100 nM fMLP for 1 min or its diluent (dimethyl sulfoxide, 0.2% v/v; control), then lysed in 1% Nonidet P-40-containing buffer. Tyrosine-phosphorylated proteins were immunoprecipitated from PMN lysates using a phosphotyrosine-specific monoclonal antibody; the resulting immunoprecipitates were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a p38-specific antibody. Panel D, PMN were stimulated for 1 min with 100 nM fMLP or its diluent (control), and p38 was immunoprecipitated. The kinase activity of the immunoprecipitates was assayed using 3 µg of glutathione S-transferase-tagged (GST)-ATF-2 as a substrate in the presence of 5 µCi of [gamma -32P]ATP. Samples were then subjected to SDS-PAGE, and radioactivity was analyzed with a PhosphorImager. Results shown are representative of three separate experiments.
[View Larger Version of this Image (42K GIF file)]


Role of PI 3-kinase in p38 Activation

We next proceeded to investigate the signaling pathway leading to the activation of p38. Activation of PI 3-kinase, which catalyzes the formation of phosphatidylinositol 3,4,5-phosphate, is one of the earliest responses of PMN to chemoattractants (31). Although the activation of PI 3-kinase in human PMN has been associated with functional events (32, 33, 34), the downstream events have yet to be defined. We therefore considered the possibility that p38 may be a target of the activation of PI 3-kinase. We tested the effects of two structurally different inhibitors of PI 3-kinase on the activation of p38 by fMLP. As shown in Fig. 2A, pretreatment of PMN for 10 min with 100 nM wortmannin resulted in a partial inhibition (60%) of the tyrosine phosphorylation of p38 in response to fMLP. Unexpectedly, a similar pretreatment of PMN with 100 µM LY294002, a second antagonist of PI 3-kinase, failed to inhibit the fMLP-induced phosphorylation of p38. In fact, pretreatment with this antagonist alone, in the absence of fMLP, induced a pronounced activation of p38, which was enhanced by the subsequent addition of the chemoattractant (Fig. 2A). Identical conclusions were reached when the kinase activity of p38 was measured using ATF-2 as a substrate (Fig. 2B). To determine whether this effect of LY294002 was specific to p38, PMN were pretreated with either wortmannin or LY294002, and the phosphorylation of Erk-1 and -2 in response to fMLP was assessed using an antibody that recognizes only the phosphorylated form of these kinases. As shown in Fig. 2C, both wortmannin and LY294002 inhibited the phosphorylation of these MAPKs to a similar extent. Therefore, the stimulatory effect of LY294002 is unique to p38. Although the underlying mechanism remains obscure, it is clear that LY294002 should be used with caution when assessing the effects of PI 3-kinase in PMN.


Fig. 2. Effect of PI 3-kinase inhibitors on the phosphorylation of MAPK in fMLP-stimulated human PMN. PMN were pretreated with 100 nM wortmannin (Wrt) or 100 µM LY294002 (LY) for 10 min and then treated with 100 nM fMLP or its diluent for 1 min. Panel A, p38 was immunoprecipitated from PMN lysates, subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a phosphotyrosine-specific antibody, as in Fig. 1A. Panel B, p38 was immunoprecipitated and then subjected to a kinase assay using glutathione S-transferase-tagged (GST)-ATF-2 as a substrate in the presence of 5 µCi of [gamma -32P]ATP. Samples were then subjected to SDS-PAGE, and radioactivity was analyzed with a PhosphorImager. Panel C, whole cell lysates were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with an antibody that recognizes only the phosphorylated forms of Erk-1 and Erk-2. Panel D, whole cell lysates were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a phosphotyrosine-specific antibody. The treatments with stimuli and/or inhibitors indicated on top apply to all three panels. Results shown are representative of three separate experiments of each type.
[View Larger Version of this Image (66K GIF file)]


Fig. 2D illustrates that, contrary to what was proposed earlier (13, 14, 15), Erk-1 and -2 are not the main approx 40-42-kDa tyrosine-phosphorylated proteins in stimulated PMN. In this experiment, cells were pretreated with wortmannin or LY294002 and then stimulated with fMLP. Immunoblotting of whole cell lysates with a phosphotyrosine-specific antibody shows that the fMLP-induced tyrosine phosphorylation of the 42-kDa band was reduced by wortmannin but not by LY294002, which in fact increased phosphorylation even in the absence of the chemoattractant. This profile parallels the effects of LY294002 on p38 and differs from its effects on Erk (cf. Fig. 2, A and C).

Role of PKC and Intracellular Calcium in p38 Activation

Several isoforms of PKC coexist in PMN and are known to be activated by chemotactic peptides. To evaluate whether PKC isoforms mediate the effect of fMLP on p38, we used a reasonably specific inhibitor, namely BIM (35). Pretreatment of PMN with 5 µM BIM for 10 min had little effect by itself but resulted in partial inhibition (65%) of the tyrosine phosphorylation of p38 induced by fMLP (Fig. 3A). To ensure that BIM was effectively inhibiting PKC, this kinase was stimulated directly with phorbol ester. Incubation of PMN with 100 nM PMA for 5 min induced a low tyrosine phosphorylation of p38. This PMA-induced tyrosine phosphorylation of p38 was fully inhibited by 5 µM BIM. These results suggest that the concentration of BIM used sufficed to inhibit PKC thoroughly. Because BIM inhibited p38 activation by fMLP only partially, and since maximally stimulatory doses of PMA yielded a response smaller than that elicited by the chemoattractant, we conclude that the response to fMLP is only partially dependent on PKC.


Fig. 3. Effect of a PKC inhibitor and calcium depletion on the tyrosine phosphorylation of p38 in fMLP-stimulated human PMN. Panel A, PMN were pretreated with or without 5 µM BIM for 10 min, then stimulated with 100 nM fMLP or its diluent for 1 min or with 100 nM PMA for 5 min. Cells were lysed, and p38 was immunoprecipitated using a p38-specific antibody, as described under "Experimental Procedures." Immunoprecipitates were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a phosphotyrosine-specific antibody. Panel B, PMN were stimulated with 100 nM fMLP or its diluent for 1 min in the absence of extracellular Ca2+ (-[Ca2+]e). Where indicated, the cells had been pretreated with 100 nM thapsigargin (thaps.) in Ca2+-free medium for 5 min or were loaded with BAPTA by incubation with 10 µM precursor acetoxymethyl ester for 30 min. After stimulation the cells were lysed, and p38 was immunoprecipitated as described for Fig. 1A. Immunoprecipitates were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a phosphotyrosine-specific antibody. Results shown are representative of three separate experiments.
[View Larger Version of this Image (45K GIF file)]


The activation of PMN by fMLP triggers an increase in cytosolic Ca2+ concentration ([Ca2+]i) which originates both from release of intracellular stores and from extracellular Ca2+ influx. The role of the cation in the activation of p38 was investigated next, using two different strategies aimed at minimizing the elevation in [Ca2+]i. In the first series of experiments, PMN were stimulated with 100 nM fMLP in the absence of extracellular Ca2+. As shown in Fig. 3B, tyrosine phosphorylation of p38 proceeded normally under these conditions. Because release from intracellular stores is the predominant component of the early response of [Ca2+]i to fMLP, omission of external Ca2+ has comparatively small effects on this response. To analyze more effectively the role of [Ca2+]i, experiments were undertaken using cells that had their internal stores depleted prior to addition of the chemoattractant. The stores were depleted using thapsigargin, an inhibitor of the endomembrane Ca2+-ATPase. Parallel experiments using indo-1 demonstrated that, following pretreatment with 100 nM thapsigargin for 5 min in Ca2+-free medium, stimulation with fMLP failed to increase [Ca2+]i (not illustrated; see Ref. 36). Using a comparable protocol, the effect of Ca2+ depletion on the phosphorylation of p38 was assessed by immunoprecipitation and blotting. The pretreatment with thapsigargin reduced, but did not eliminate, the tyrosine phosphorylation of p38 (see Fig. 5). It is noteworthy that the transient elevation in [Ca2+]i which accompanies inhibition of the ATPase by thapsigargin in Ca2+-free medium had no effect on p38 phosphorylation.


Fig. 5. Phosphorylation of HSP27 by MAPKAPK-2 in fMLP-stimulated human PMN. Panel A, PMN were stimulated for 1 min with 100 nM fMLP, and MAPKAPK-2 was immunoprecipitated as described under "Experimental Procedures." The kinase activity of the immune complexes was assayed by incubation with 3 µg of HSP27 and 5 µCi of [gamma -32P]ATP. Following SDS-PAGE, phosphorylation of HSP27 was analyzed with a PhosphorImager. Panel B, the autoradiogram shown in panel A was exposed for a longer period of time to reveal the autophosphorylation of a 50-kDa band, likely MAPKAPK-2. For clarity, only the mid portion of the radiogram is illustrated. Panel C, PMN that were either unstimulated (open squares) or stimulated with 100 nM fMLP for 1 min (solid squares) or 2 min (triangles) were lysed in 1% Nonidet P-40 buffer. The soluble fraction was then fractionated using a Mono Q column. Fractions were collected and assayed for HSP27 kinase activity as described under "Experimental Procedures" (top panel). Collected fractions were also subjected to SDS-PAGE and blotted with a polyclonal MAPKAPK-2-specific antibody (bottom panel; the fraction numbers are indicated below the blot). Results shown are representative of three separate experiments.
[View Larger Version of this Image (28K GIF file)]


The role of [Ca2+]i was also analyzed in cells loaded with BAPTA, an effective Ca2+-chelating agent. Under the conditions used, BAPTA virtually eliminates the [Ca2+]i transient elicited by fMLP, as measured with indo-1 (not shown). As in the case of thapsigargin, obliteration of the [Ca2+]i transient with BAPTA only partially inhibited (70%) the chemoattractant-induced tyrosine phosphorylation of p38. Together, these observations indicate that elevated [Ca2+]i is not sufficient, nor is it absolutely necessary, to activate p38.

Activation of MAPKAPK-2 by fMLP in Human PMN

p38 was proposed to be an upstream activator of MAPKAPK-2. This suggestion is based on the ability of p38 to reactivate dephosphorylated, inactive MAPKAPK-2 (27). Because p38 was found to be activated by fMLP, we next determined whether MAPKAPK-2 is also present and activated by chemoattractants in PMN. A single highly immunoreactive band of 50 kDa was detected in PMN lysates by the MAPKAPK-2 antibody (Fig. 4). Upon stimulation with fMLP, a progressive decrease in the electrophoretic mobility of MAPKAPK-2 was noticed. The shift was detectable within 30 s, reached maximal levels around 1 min, and persisted for up to 10 min.


Fig. 4. fMLP-induced MAPKAPK-2 phosphorylation in human PMN. Cells were stimulated with 100 nM fMLP for the specified periods of time. Whole cell lysates (106 cell equivalents) were then subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a polyclonal MAPKAPK-2-specific antibody. The positions of two distinct forms of MAPKAPK-2, presumed to be the phosphorylated and unphosphorylated species, are indicated.
[View Larger Version of this Image (17K GIF file)]


To define whether MAPKAPK-2 is indeed phosphorylated and activated upon fMLP stimulation of PMN, the kinase was immunoprecipitated from cells treated with or without the chemoattractant. The immune complexes were tested for kinase activity using HSP27 as a substrate. Fig. 5A illustrates that stimulation of the cells with fMLP induced a marked increase in the ability of MAPKAPK-2 to phosphorylate HSP27. A second phosphorylated band of approx 50 kDa was also noticeable in fMLP-stimulated samples, which became clearly apparent upon longer exposure of the radiograms (Fig. 5B). Although fainter than the HSP27 band, the 50-kDa band was consistently observed and likely represents autophosphorylated MAPKAPK-2 (37).

Independent evidence that MAPKAPK-2 is activated by fMLP and is responsible for the HSP27 kinase activity in stimulated PMN was obtained by subjecting cell lysates to Mono Q chromatography. In chemoattractant-stimulated PMN, an increase in HSP27 kinase activity was detected in fractions 21-23 (Fig. 5C). The collected fractions were also analyzed by SDS-PAGE, and the distribution of MAPKAPK-2 was tested by immunoblotting. Using the polyclonal MAPKAPK-2-specific antibody, immunoreactive bands were observed in the same fractions that displayed stimulated HSP27 kinase activity. These results thus demonstrate the presence of a 50-kDa MAPKAPK-2 in human PMN which possesses HSP27-kinase activity, which is stimulated by fMLP.

Because p38 activity was affected differentially by wortmannin and LY294002, we used these agents to define whether this kinase or Erk is responsible for the phosphorylation and activation of MAPKAPK-2. As shown in Fig. 6A, pretreatment of PMN with wortmannin partially inhibited the electrophoretic mobility of MAPKAPK-2 induced by fMLP. Moreover, as observed for p38 in Fig. 3A, pretreatment with LY294002 alone induced the electrophoretic mobility shift of MAPKAPK-2. Subsequent stimulation with fMLP further potentiated the band shift. That the mobility shift was an indication of an active MAPKAPK-2 was confirmed with a kinase assay. Fig. 6, B and C, shows that the autophosphorylation of MAPKAPK-2 and the phosphorylation of HSP27, respectively, were inhibited similarly by wortmannin and stimulated by LY294002, as observed previously for p38. These results indicate that the regulation of MAPKAPK-2 by PI 3-kinase closely resembles that of p38 and clearly differs from those of Erk-1 and -2. 


Fig. 6. Effect of PI 3-kinase inhibitors on the phosphorylation and activation of MAPKAPK-2 induced by fMLP. PMN were stimulated with 100 nM fMLP (F) in the presence or absence of 100 nM wortmannin (Wrt) or 100 µM LY294002 (LY). Panel A, whole cell lysates (106 cell equivalents) were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a MAPKAPK-2-specific antibody. Panel B, stimulated cells were lysed, and MAPKAPK-2 was immunoprecipitated and incubated in the presence of 5 µCi of [gamma -32P]ATP and 3 µg of HSP27. The region corresponding to the autophosphorylated form of MAPKAPK-2 is illustrated. Panel C, the phosphorylation of HSP27 is illustrated. Results shown are representative of three separate experiments.
[View Larger Version of this Image (53K GIF file)]


That p38, and not Erk, is the upstream activator of MAPKAPK-2 was confirmed by pretreating PMN with a specific inhibitor of p38, namely SB203580 (17). Pretreatment of PMN for 20 min with 10 µM SB203580 completely eliminated the electrophoretic mobility shift of MAPKAPK-2 upon stimulation with fMLP (Fig. 7A). More direct evidence of the effect of SB203580 on the activity of MAPKAPK-2 was obtained by quantifying its autophosphorylation (Fig. 7B) and its ability to phosphorylate HSP27 in vitro (Fig. 7C). SB203580 consistently eliminated the activation of MAPKAPK-2 in PMN stimulated by fMLP.


Fig. 7. Effect of SB203580 on the phosphorylation and activation of MAPKAPK-2 in fMLP-stimulated human PMN. PMN were stimulated with 100 nM fMLP or its diluent in the presence or absence of 10 µM SB203580 (SB). Panel A, whole cell lysates (106 cell equivalents) were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a MAPKAPK-2-specific antibody. Panel B, stimulated cells were lysed, and MAPKAPK-2 was immunoprecipitated and incubated in the presence of 5 µCi of [gamma -32P]ATP and 3 µg of HSP27. The region corresponding to the autophosphorylated form of MAPKAPK-2 is illustrated. Panel C, the phosphorylation of HSP27 is illustrated.
[View Larger Version of this Image (36K GIF file)]


Association of p38 with MAPKAPK-2 in Human PMN

Since the phosphorylation and activation of MAPKAPK-2 and p38 occur in parallel, we explored the possibility that these two kinases might physically associate in vivo. In the first series of experiments, MAPKAPK-2 was immunoprecipitated, and the presence of p38 in the immune complexes was assessed. The results of one such experiment are illustrated in Fig. 8A (left panel). An immunoreactive band of 42 kDa was detected in both untreated and fMLP-stimulated PMN, suggesting an association between MAPKAPK-2 and p38. Of note, lower amounts of p38 were consistently detected in the immune complexes following stimulation of cells with fMLP. This observation suggests that dissociation of the complex occurred upon activation of p38 and/or MAPKAPK-2. However, at least part of the active p38 remains associated with MAPKAPK-2, since clear immunoreactivity at 42 kDa was detectable when MAPKAPK-2 precipitates were blotted with anti-phosphotyrosine antibodies (Fig. 8A, right panel). Accordingly, MAPKAPK-2 precipitates obtained from fMLP-stimulated cells displayed kinase activity toward ATF-2, indicative of associated p38 activity and p38 immunoprecipitates contained HSP27 kinase activity (Fig. 8B). The interaction between the two kinases was also probed using the reverse protocol, i.e. immunoprecipitation of p38 followed by detection of MAPKAPK-2. However, immunoblotting of such precipitates with anti-MAPKAPK-2 antibody did not yield conclusive results because of the close proximity of the immunoglobulin heavy chain (53 kDa) with MAPKAPK-2 (not shown).


Fig. 8. Association of p38 with MAPKAPK-2 in human PMN. PMN were treated with or without 100 nM fMLP for 1 min, lysed, and used for immunoprecipitation of p38 or MAPKAPK-2 as described under "Experimental Procedures." Panel A, immunoprecipitates of MAPKAPK-2 were subjected to SDS-PAGE, transferred to PVDF membranes, and blotted with a p38-specific antibody (left) or with a phosphotyrosine-specific antibody (right). Panel B. Left, the kinase activity of immunoprecipitates of MAPKAPK-2 was assayed using ATF-2 as a substrate. Right, the kinase activity of immunoprecipitates of p38 was assayed using HSP27 as a substrate. Results shown in panels A and B are representative of three separate experiments of each kind.
[View Larger Version of this Image (52K GIF file)]



DISCUSSION

Stimulation of PMN by chemotactic peptides leads to the phosphorylation of several intracellular proteins that are believed to participate in the activation of the microbicidal function of these cells. In the present study we described the presence of p38 and MAPKAPK-2 in human PMN and their activation by fMLP which was found to be rapid and transient. This result contrasts with the much slower activation of p38 induced by cytokines or environmental stresses, which has been found to peak after 15-30 min (21). Moreover, we provided evidence that these kinases are associated with each other in quiescent cells and that their dissociation is facilitated by chemotactic stimulation.

The kinase(s) directly responsible for the phosphorylation and activation of p38 in human PMN have yet to be determined. At least three dual specificity kinases, MKK3 (37), MKK4 (37, 38), and MKK6 (39), possess the ability to phosphorylate p38. However, their presence and role toward p38 activation in PMN remain to be defined. Recent studies have shown that p38 can be activated in cells transfected with constitutively active Rac or Cdc42 (40, 41, 42) possibly via a <UNL>p</UNL>21-<UNL>a</UNL>ctivated <UNL>k</UNL>inase (PAK) (40). This notion stems from the demonstration that overexpression of a dominant-negative PAK prevented the activation of p38 induced by Rac or Cdc42. It is therefore attractive to suggest that one pathway leading to p38 activation by fMLP in PMN involves Rac and/or Cdc42, followed by PAK. Indeed, two isoforms of PAK have been detected in human PMN, where they can be activated by fMLP (43). Moreover, Knaus et al. (43) noted that PAK activation by fMLP includes a PI 3-kinase-dependent step, which may explain the inhibitory effect of wortmannin on p38 reported in the present study. It is clear, however, that an additional pathway(s) must contribute to the activation of p38, since only partial inhibition was obtained with a concentration of wortmannin known to block PI 3-kinase completely. That an additional pathway may involve PKC is suggested by the following observations. First, the activation of p38 was partially prevented by BIM, a PKC inhibitor. Second, PMA, a direct activator of PKC, also induced partial activation of p38. Finally, obliteration of the cytosolic Ca2+ transient triggered by fMLP resulted in a degree of inhibition comparable to that observed with BIM. It is thus tempting to speculate that Ca2+-sensitive isoforms of PKC, such as the alpha  or beta  isoenzymes, may be involved in the activation of p38. These two conventional isoforms of PKC have, in fact, been detected in human PMN (44, 45, 46). That the PKC-dependent pathway of p38 activation is independent of PAK is suggested by the fact that PMA is unable to activate PAK in human PMN (43). Interestingly, the inhibitory effects of wortmannin and BIM on p38 activation are not additive (results not shown), suggesting convergence of these pathways and the existence of additional activating signals.

The results we obtained with two distinct inhibitors of PI 3-kinase yielded an apparent discrepancy. Although wortmannin partially blocked the activation of p38, LY294002 had little inhibitory activity and, in fact, markedly stimulated the kinase even in the absence of chemoattractants. The mechanisms of inhibition of these agents are different: wortmannin is an alkylating agent, producing irreversible inhibition of PI 3-kinase (47), whereas LY294002 is a competitive antagonist of the ATP binding site of the lipid kinase (48). Another possible target of wortmannin and LY294002 may be found in <UNL>r</UNL>apamycin <UNL>n</UNL>nd <UNL>F</UNL>KBP12 <UNL>t</UNL>arget (RAFT, the mammalian homolog of the yeast TOR), which has homology to the lipid kinase domain of PI 3-kinase and PI 4-kinase (49). It is tempting to speculate that RAFT might be upstream of p38 and that LY294002 and wortmannin modulate differentially the kinase activity of RAFT, through its lipid kinase domain. However, the presence of RAFT in human PMN and its regulation have yet to be uncovered. Since both PI 3-kinase inhibitors were comparably effective in suppressing the fMLP-induced activation of Erk-1 and -2, it is likely that PI 3-kinase was inhibited in both instances, as expected from the concentrations of the antagonists used, based on earlier literature (33). It is therefore reasonable to assume that LY294002 has an additional effect on PMN, independent of its inhibition of PI 3-kinase. Alternatively, LY294002 may be able to activate purinergic receptors on the surface of PMN (50), which may in turn lead to activation of p38. Also, the effect of the comparatively large (100 µM) doses of LY294002 may be stress-related; indeed, unlike Erk-1 and -2, p38 is activated by several types of stress, including chemical stress. Clearly, further studies are required to establish the mechanism by which LY294002 stimulates p38.

MAPKAPK-2 is activated in vitro by Erk-1 and Erk-2 (51) and also by p38 (23, 27). However, it has become increasingly apparent that in vivo only p38 is able to phosphorylate and activate MAPKAPK-2 (23, 27, 52). Our experiments revealed the presence of MAPKAPK-2 in PMN and established fMLP as a potent activator of this kinase. Because Erk-1 and -2 are also stimulated by fMLP, the possibility existed that MAPKAPK-2 was phosphorylated by these kinases instead of, or in addition to, p38. However, several lines of evidence argue against this possibility. First, LY294002, which inhibited Erk-1 and 2 but not p38, failed to inhibit MAPKAPK-2. Second, SB203580, which has no discernible effects on Erk-1 or -2 (17, 52), prevented the phosphorylation of MAPKAPK-2. Additionally, although we observed a constitutive association between p38 and MAPKAPK-2 in vivo, the latter was never detected to interact with Erk-1 and -2 in either untreated or fMLP-treated PMN (results not shown).

The ability of a member of the MAPK family to form heterodimeric complexes with other kinases in vivo is not without precedent. Hsiao et al. (53) noted that inactive Erk-2 associates with p90rsk in Xenopus oocytes; upon activation the complex was found to dissociate. Moreover, McLaughlin et al. (54) observed that in its inactive form, MAPKAPK-3 associates with p38 and that the interaction is disrupted upon exposure of the cells to hypertonic sorbitol, a treatment known to activate stress kinases. These interactions resemble the association between MAPKAPK-2 and p38 reported here. In other systems multiple kinases appear to be maintained in elaborate complexes by specific docking proteins (55). It will be of interest to determine whether additional kinases and/or docking proteins are found complexed with MAPKAPK-2 and p38 in PMN. Identification of the constituents of such putative complexes may help us understand the role of p38 and MAPKAPK-2 in the functional responses of PMN.


FOOTNOTES

*   This work was supported in part by the Medical Research Council of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Recipient of a Medical Research Council postdoctoral fellowship.
**   International Scholar of the Howard Hughes Medical Institute. To whom correspondence should be addressed: Division of Cell Biology, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. Tel.: 416-813-5727; Fax: 416-813-5028; E-mail: sga{at}sickkids.on.ca.
1    The abbreviations used are: PMN, polymorphonuclear leukocyte(s); fMLP, N-formyl-methionyl-leucyl-phenylalanine; Erk, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MAPKAPK-2, MAPK-activated protein kinase-2; HSP27, heat shock protein 27; PI 3-kinase, phosphatidylinositol 3-kinase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; BIM, bis-indolylmaleimide I; PAGE, polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; MOPS, 4-morpholinepropanesulfonic acid; PAK, p21-activated kinase; RAFT, rapamycin and FKBP12 target.

REFERENCES

  1. Baggiolini, M., and Kerner, P. (1992) News Physiol. Sci. 7, 215-219 [Abstract/Free Full Text]
  2. Snyderman, R., and Uhing, R. J. (1992) in Inflammation: Basic Principles and Clinical Correlates (Gallin, J. I., Goldstein, I. M., and Snyderman, R., eds), p. 421, Raven Press, New York
  3. Andrews, P. C., and Babior, B. M. (1983) Blood 61, 333-340 [Abstract]
  4. Berkow, R., and Dodson, R. W. (1990) Blood 75, 2445-2452 [Abstract]
  5. Grinstein, S., Furuya, W., Butler, J. R., and Tseng, J. (1993) J. Biol. Chem. 268, 20223-20231 [Abstract/Free Full Text]
  6. Niessen, H. W. N., and Verhoeven, A. J. (1994) Biochim. Biophys. Acta 1223, 267-273 [Medline] [Order article via Infotrieve]
  7. Naccache, P. H., Gilbert, C., Caon, A. C., Gaudry, M., Huang, C.-K., Bonak, V. A., Umezawa, K., and McColl, S. R. (1990) Blood 76, 2098-2104 [Abstract]
  8. Ding, J., and Badwey, J. A. (1992) J. Biol. Chem. 267, 6442-6448 [Abstract/Free Full Text]
  9. Kusunoki, T., Higashi, H., Hosoi, S., Hata, D., Sugie, K., Mayumi, M., and Mikawa, H. (1992) Biochem. Biophys. Res. Commun. 183, 789-796 [Medline] [Order article via Infotrieve]
  10. Berkow, R. L., and Dodson, R. W. (1993) Life Sci. 52, 1727-1732 [Medline] [Order article via Infotrieve]
  11. Wenzel-Seifert, K., Schachtele, C., and Seifert, R. (1994) Biochem. Biophys. Res. Commun. 200, 1536-1543 [CrossRef][Medline] [Order article via Infotrieve]
  12. Merritt, J. E., Moores, K. E., Evans, A. T., Sharma, P., Evans, F. J., and MacPhee, C. H. (1993) Biochem. J. 289, 919-926 [Medline] [Order article via Infotrieve]
  13. Grinstein, S., and Furuya, W. (1992) J. Biol. Chem. 267, 18122-18125 [Abstract/Free Full Text]
  14. Torres, M., Hall, F. L., and O'Neill, K. (1993) J. Immunol. 150, 1563-1578 [Abstract/Free Full Text]
  15. Thompson, H. L., Shiroo, M., and Saklatvala, J. (1993) Biochem. J. 290, 483-488 [Medline] [Order article via Infotrieve]
  16. Han, J., Lee, J.-D., Bibbs, L., and Ulevitch, R. J. (1994) Science 265, 808-811 [Medline] [Order article via Infotrieve]
  17. Lee, J. C., Layton, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739-746 [CrossRef][Medline] [Order article via Infotrieve]
  18. Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037 [Medline] [Order article via Infotrieve]
  19. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160 [CrossRef][Medline] [Order article via Infotrieve]
  20. Galcheva-Gargova, Z., Dérijard, B., Wu, I.-H., and Davis, R. J. (1994) Science 265, 806-808 [Medline] [Order article via Infotrieve]
  21. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) J. Biol. Chem. 270, 7420-7426 [Abstract/Free Full Text]
  22. Brewster, J. L., De Valoir, T., Dyer, N. D., Winter, E., and Gustin, M. C. (1993) Science 259, 1760-1763 [Medline] [Order article via Infotrieve]
  23. Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) Cell 78, 1027-1037 [Medline] [Order article via Infotrieve]
  24. Han, J., Richter, B., Li, Z., Kravchenko, V. V., and Ulevitch, R. J. (1995) Biochem. Biophys. Acta 1265, 224-227 [Medline] [Order article via Infotrieve]
  25. Shapiro, L., and Dinarello, C. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 12230-12234 [Abstract]
  26. Saklatvala, J., Rawlinson, L., Waller, R. J., Sarsfield, S., Lee, J. C., Morton, L. F., Barnes, M. J., and Farndale, R. W. (1996) J. Biol. Chem. 271, 6586-6589 [Abstract/Free Full Text]
  27. Freshney, N. W., Rawlinson, L., Guesdon, F., Jones, E., Cowley, S., Hsuan, J., and Saklatvala, J. (1994) Cell 78, 1039-1049 [Medline] [Order article via Infotrieve]
  28. Lavoie, J. N., Hickey, E., Weber, L. A., and Landry, J. (1993) J. Biol. Chem. 268, 24210-24214 [Abstract/Free Full Text]
  29. Lavoie, J. N., Lambert, H., Hickey, E., Weber, L. A., and Landry, J. (1995) Mol. Cell Biol. 15, 505-516 [Abstract]
  30. Boyum, A. (1968) Scand. J. Clin. Lab. Invest. 21, 77-89 [Medline] [Order article via Infotrieve]
  31. Traynor-Kaplan, A. E., Thompson, B. L., Harris, A. L., Taylor, P., Omann, G. M., and Sklar, L. A. (1989) J. Biol. Chem. 264, 15668-15673 [Abstract/Free Full Text]
  32. Eberle, M., Traynor-Kaplan, A. E., Sklar, L. A., and Norgauer, J. (1990) J. Biol. Chem. 265, 16725-16728 [Abstract/Free Full Text]
  33. Vlahos, C. J., Matter, W. F., Brown, R. F., Traynor-Kaplan, A. E., Heyworth, P. G., Prossnitz, E. R., Ye, R. D., Marder, P., Schelm, J. A., Rothfuss, K. J., Serlin, B. S., and Simpson, P. J. (1995) J. Immunol. 154, 2413-2422 [Abstract/Free Full Text]
  34. Knall, C., Young, S., Nick, J. A., Buhl, A. M., Worthen, G. S., and Johnson, G. L. (1996) J. Biol. Chem. 271, 2832-2838 [Abstract/Free Full Text]
  35. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. (1991) J. Biol. Chem. 266, 15771-15781 [Abstract/Free Full Text]
  36. Grinstein, S., Butler, J. R., Furuya, W., L'Allemain, G., and Downey, G. P. (1994) J. Biol. Chem. 269, 19313-19320 [Abstract/Free Full Text]
  37. Dérijard, B., Raingeaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685 [Medline] [Order article via Infotrieve]
  38. Lin, A., Minden, A., Martinetto, H., Claret, F.-X., Lange-Carter, C., Mercurio, F., Johnson, G. L., and Karin, M. (1995) Science 268, 286-290 [Medline] [Order article via Infotrieve]
  39. Han, J., Lee, J.-D., Jiang, Y., Li, Z., Feng, L., and Ulevitch, R. J. (1996) J. Biol. Chem. 271, 2886-2891 [Abstract/Free Full Text]
  40. Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., and Bokoch, G. M. (1995) J. Biol. Chem. 270, 23934-23936 [Abstract/Free Full Text]
  41. Bagrodia, S., Dérijard, B., Davis, R. J., and Cerione, R. A. (1995) J. Biol. Chem. 270, 27995-27998 [Abstract/Free Full Text]
  42. Minden, A., Lin, A., Claret, F.-X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157 [Medline] [Order article via Infotrieve]
  43. Knaus, U. G., Morris, S., Dong, H.-J., Chernoff, J., and Bokoch, G. M. (1995) Science 269, 221-223 [Medline] [Order article via Infotrieve]
  44. Pontremoli, S., Melloni, E., Sparatore, B., Michetti, M., Salamino, F., and Horecker, B. L. (1990) J. Biol. Chem. 265, 706-712 [Abstract/Free Full Text]
  45. Majumdar, S., Rossi, M. W., Fujiki, T., Phillips, W. A., Disa, S., Queen, C. F., Johnston, R. B., Jr., Rosen, O. M., Corkey, B. E., and Korchak, H. M. (1991) J. Biol. Chem. 266, 9285-9294 [Abstract/Free Full Text]
  46. Smallwood, J. I., and Malawista, S. E. (1992) J. Leukocyte Biol. 51, 84-92 [Abstract]
  47. Powis, G., Bonjouklian, R., Berggren, M., Gallegos, A., Abraham, R., Ashendel, C., Zalkow, L., Matter, W. F., Dodge, J., Grindey, G., and Vlahos, C. J. (1994) Cancer Res. 54, 2419-2423 [Abstract]
  48. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994) J. Biol. Chem. 269, 5241-5248 [Abstract/Free Full Text]
  49. Sabatini, D. M., Pierchala, B. A., Barrow, R. K., Schell, M. J., and Snyder, S. H. (1995) J. Biol. Chem. 270, 20875-20878 [Abstract/Free Full Text]
  50. Walker, B. A., Hagenlocker, B. E., Douglas, V. K., Tarapchak, S. J., and Ward, P. A. (1991) Lab. Invest. 64, 105-112 [Medline] [Order article via Infotrieve]
  51. Stokoe, D., Campbell, D. G., Nakielny, S., Hidaka, H., Leevers, S. J., Marshall, C., and Cohen, P. (1992) EMBO J. 11, 3985-3994 [Abstract]
  52. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. (1995) FEBS Lett. 364, 229-233 [CrossRef][Medline] [Order article via Infotrieve]
  53. Hsiao, K.-M., Chou, S.-Y., Shih, S.-J., and Ferrel, J. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5480-5484 [Abstract]
  54. McLaughlin, M. M., Kumar, S., McDonnell, P. C., Van Horn, S., Lee, J. C., Livi, G. P., and Young, P. R. (1996) J. Biol. Chem. 271, 8488-8492 [Abstract/Free Full Text]
  55. Elion, E. A. (1995) Trends Cell. Biol. 5, 322-327 [CrossRef]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.